Butorphanol Tartrate en es it fr

Butorphanol Tartrate Brand names, Butorphanol Tartrate Analogs

Butorphanol Tartrate Brand Names Mixture

  • No information avaliable

Butorphanol Tartrate Chemical_Formula


Butorphanol Tartrate RX_link


Butorphanol Tartrate fda sheet

Butorphanol_Tartrate FDA

Butorphanol Tartrate msds (material safety sheet)

Butorphanol_Tartrate MSDS

Butorphanol Tartrate Synthesis Reference

No information avaliable

Butorphanol Tartrate Molecular Weight

327.461 g/mol

Butorphanol Tartrate Melting Point

No information avaliable

Butorphanol Tartrate H2O Solubility


Butorphanol Tartrate State


Butorphanol Tartrate LogP


Butorphanol Tartrate Dosage Forms

Drops; Drug premix; Gel; Globules; Liquid; Powder for solution; Solution; Spray; Tablet

Butorphanol Tartrate Indication

For the management of pain when the use of an opioid analgesic is appropriate. Also indicated as a preoperative or preanesthetic medication, as a supplement to balanced anesthesia, and for the relief of pain during labor.

Butorphanol Tartrate Pharmacology

Butorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord.

Butorphanol Tartrate Absorption

Rapidly absorbed after intramuscular injection and peak plasma levels are reached in 20-40 minutes. The absolute bioavailability is 60-70% and is unchanged in patients with allergic rhinitis. In patients using a nasal vasoconstrictor (oxymetazoline) the fraction of the dose absorbed was unchanged, but the rate of absorption was slowed. Oral bioavailability is only 5-17% because of extensive first-pass metabolism.

Butorphanol Tartrate side effects and Toxicity

The clinical manifestations of butorphanol overdose are those of opioid drugs in general. The most serious symptoms are hypoventilation, cardiovascular insufficiency, coma, and death.

Butorphanol Tartrate Patient Information

Butorphanol Tartrate Organisms Affected

Humans and other mammals